Note: As FDA indexes SPL, only VA MED-RT and NDF-RT Classifications that the FDA considers scientifically valid and clinically meaningful are used. Therefore, the drug classes that are available for a DailyMed query represent a subset of all VA MED-RT and NDF-RT classifications.
To find drugs that belong to a specific drug class, type in the drug class in the search box or select from the list of drug classes.
SEARCH RESULTS FOR:
NO SEARCH TERM (Restricted to VA MED-RT/NDF-RT - Mechanism of Action) [291 Results Found]
- 5-alpha Reductase Inhibitors [MoA]
- 5-Lipoxygenase Inhibitors [MoA]
- Acetyl Aldehyde Dehydrogenase Inhibitors [MoA]
- Acetylcholine Release Inhibitors [MoA]
- Acidifying Activity [MoA]
- Adenosine Receptor Agonists [MoA]
- Adrenal Steroid Synthesis Inhibitors [MoA]
- Adrenergic Agonists [MoA]
- Adrenergic alpha1-Agonists [MoA]
- Adrenergic alpha2-Agonists [MoA]
- Adrenergic alpha-Agonists [MoA]
- Adrenergic alpha-Antagonists [MoA]
- Adrenergic beta1-Antagonists [MoA]
- Adrenergic beta2-Agonists [MoA]
- Adrenergic beta2-Antagonists [MoA]
- Adrenergic beta3-Agonists [MoA]
- Adrenergic beta-Agonists [MoA]
- Adrenergic beta-Antagonists [MoA]
- Aldosterone Antagonists [MoA]
- Alkylating Activity [MoA]
- alpha Glucosidase Inhibitors [MoA]
- alpha-Particle Emitting Activity [MoA]
- Ammonium Ion Binding Activity [MoA]
- AMPA Receptor Antagonists [MoA]
- Amylin Agonists [MoA]
- Androgen Receptor Agonists [MoA]
- Androgen Receptor Antagonists [MoA]
- Angiotensin 2 Receptor Antagonists [MoA]
- Angiotensin 2 Type 1 Receptor Antagonists [MoA]
- Angiotensin-converting Enzyme Inhibitors [MoA]
- Anthrax Protective Antigen-directed Antibody Interactions [MoA]
- Antibody-Surface Protein Interactions [MoA]
- Antigen Neutralization [MoA]
- Aromatase Inhibitors [MoA]
- Bacterial Neurotoxin Neutralization [MoA]
- beta Lactamase Inhibitors [MoA]
- Bile-acid Binding Activity [MoA]
- B Lymphocyte Stimulator-directed Antibody Interactions [MoA]
- Bradykinin B2 Receptor Antagonists [MoA]
- Breast Cancer Resistance Protein Inhibitors [MoA]
- Calcineurin Inhibitors [MoA]
- Calcium Channel Antagonists [MoA]
- Calcium Chelating Activity [MoA]
- Carbamoyl Phosphate Synthetase 1 Activators [MoA]
- Carbonic Anhydrase Inhibitors [MoA]
- Catecholamine Synthesis Inhibitors [MoA]
- Catechol O-Methyltransferase Inhibitors [MoA]
- CD19-directed Antibody Interactions [MoA]
- CD20-directed Antibody Interactions [MoA]
- CD22-directed Antibody Interactions [MoA]
- CD30-directed Antibody Interactions [MoA]
- CD33-directed Antibody Interactions [MoA]
- CD38-directed Antibody Interactions [MoA]
- CD3-directed Antibody Interactions [MoA]
- CD3 Receptor Agonists [MoA]
- CD52-directed Antibody Interactions [MoA]
- CD80-directed Antibody Interactions [MoA]
- CD86-directed Antibody Interactions [MoA]
- Chelating Activity [MoA]
- Chemokine Co-receptor 5 Antagonists [MoA]
- Chloride Channel Activation Potentiators [MoA]
- Chloride Channel Activators [MoA]
- Cholinergic Agonists [MoA]
- Cholinergic Antagonists [MoA]
- Cholinergic Muscarinic Agonists [MoA]
- Cholinergic Muscarinic Antagonists [MoA]
- Cholinesterase Inhibitors [MoA]
- Cholinesterase Reactivators [MoA]
- Competitive Opioid Antagonists [MoA]
- Complement Inhibitors [MoA]
- Corticosteroid Hormone Receptor Agonists [MoA]
- CTLA-4-directed Antibody Interactions [MoA]
- Cyclooxygenase Inhibitors [MoA]
- Cystine Disulfide Reduction [MoA]
- Cytochrome P450 17A1 Inhibitors [MoA]
- Cytochrome P450 1A2 Inducers [MoA]
- Cytochrome P450 1A2 Inhibitors [MoA]
- Cytochrome P450 1A Inducers [MoA]
- Cytochrome P450 2B6 Inducers [MoA]
- Cytochrome P450 2B6 Inhibitors [MoA]
- Cytochrome P450 2C19 Inducers [MoA]
- Cytochrome P450 2C19 Inhibitors [MoA]
- Cytochrome P450 2C8 Inducers [MoA]
- Cytochrome P450 2C8 Inhibitors [MoA]
- Cytochrome P450 2C9 Inducers [MoA]
- Cytochrome P450 2C9 Inhibitors [MoA]
- Cytochrome P450 2D6 Inducers [MoA]
- Cytochrome P450 2D6 Inhibitors [MoA]
- Cytochrome P450 3A4 Inducers [MoA]
- Cytochrome P450 3A4 Inhibitors [MoA]
- Cytochrome P450 3A5 Inhibitors [MoA]
- Cytochrome P450 3A Inducers [MoA]
- Cytochrome P450 3A Inhibitors [MoA]
- Decarboxylase Inhibitors [MoA]
- Demulcent Activity [MoA]
- Dihydrofolate Reductase Inhibitors [MoA]
- Dihydroorotate Dehydrogenase Inhibitors [MoA]
- Dipeptidase Inhibitors [MoA]
- Dipeptidyl Peptidase 4 Inhibitors [MoA]
- DNA Polymerase Inhibitors [MoA]
- DNA Terminase Complex Inhibitors [MoA]
- DOPA Decarboxylase Inhibitors [MoA]
- Dopamine Agonists [MoA]
- Dopamine D2 Antagonists [MoA]
- Dopamine Uptake Inhibitors [MoA]
- Dyes [MoA]
- Endogenous Antigen Neutralization [MoA]
- Endothelin Receptor Antagonists [MoA]
- Epoxide Hydrolase Inhibitors [MoA]
- Estrogen Receptor Agonists [MoA]
- Estrogen Receptor Antagonists [MoA]
- Factor Xa Inhibitors [MoA]
- Farnesoid X Receptor Agonists [MoA]
- Folic Acid Metabolism Inhibitors [MoA]
- Free Radical Scavenging Activity [MoA]
- Full Opioid Agonists [MoA]
- Fusion Protein Inhibitors [MoA]
- GABA A Agonists [MoA]
- GABA B Agonists [MoA]
- Glucagon-like Peptide-1 (GLP-1) Agonists [MoA]
- Glucagon-like Peptide-2 (GLP-2) Agonists [MoA]
- Glucosylceramide Synthase Inhibitors [MoA]
- Glycolipid Disialoganglioside-directed Antibody Interactions [MoA]
- Gonadotropin Releasing Hormone Receptor Agonists [MoA]
- Gonadotropin Releasing Hormone Receptor Antagonists [MoA]
- Growth Hormone Receptor Antagonists [MoA]
- Growth Hormone Secretagogue Receptor Agonists [MoA]
- Guanylate Cyclase Activators [MoA]
- Guanylate Cyclase Stimulators [MoA]
- HCV NS3/4A Protease Inhibitors [MoA]
- Heparin Binding Activity [MoA]
- HER1 Antagonists [MoA]
- HER2/Neu/cerbB2 Antagonists [MoA]
- Histamine H1 Receptor Antagonists [MoA]
- Histamine H2 Receptor Antagonists [MoA]
- Histamine Receptor Antagonists [MoA]
- Histone Deacetylase Inhibitors [MoA]
- HIV Integrase Inhibitors [MoA]
- HIV Protease Inhibitors [MoA]
- Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA]
- Hydroxyphenylpyruvate Dioxygenase Inhibitors [MoA]
- Hyperpolarization-activated Cyclic Nucleotide-gated Channel Antagonists [MoA]
- IgE-directed Antibody Interactions [MoA]
- Increased Calcium-sensing Receptor Sensitivity [MoA]
- Integrin Receptor Antagonists [MoA]
- Interferon Inducers [MoA]
- Interleukin-12 Antagonists [MoA]
- Interleukin-17A Antagonists [MoA]
- Interleukin 17 Receptor A Antagonists [MoA]
- Interleukin 1 Receptor Antagonists [MoA]
- Interleukin-23 Antagonists [MoA]
- Interleukin 2 Receptor Antagonists [MoA]
- Interleukin 2 Receptor-directed Antibody Interactions [MoA]
- Interleukin 4 Receptor alpha Antagonists [MoA]
- Interleukin-5 Antagonists [MoA]
- Interleukin 5 Receptor alpha-directed Antibody Interactions [MoA]
- Interleukin-6 Antagonists [MoA]
- Interleukin 6 Receptor Antagonists [MoA]
- Ion Exchange Activity [MoA]
- Iron Chelating Activity [MoA]
- Irrigation [MoA]
- Isocitrate Dehydrogenase 2 Inhibitors [MoA]
- Janus Kinase Inhibitors [MoA]
- Kallikrein Inhibitors [MoA]
- Kinase Inhibitors [MoA]
- Lead Chelating Activity [MoA]
- Leukotriene Receptor Antagonists [MoA]
- Lipase Inhibitors [MoA]
- Lymphocyte Function-Associated Antigen-1 Antagonists [MoA]
- M2 Protein Inhibitors [MoA]
- Magnesium Ion Exchange Activity [MoA]
- Magnetic Resonance Contrast Activity [MoA]
- Melanin Synthesis Inhibitors [MoA]
- Melatonin Receptor Agonists [MoA]
- Metal Chelating Activity [MoA]
- Methylating Activity [MoA]
- Microsomal Triglyceride Transfer Protein Inhibitors [MoA]
- Monoamine Oxidase-B Inhibitors [MoA]
- Monoamine Oxidase Inhibitors [MoA]
- mTOR Inhibitors [MoA]
- Multidrug and Toxin Extrusion Transporter 1 Inhibitors [MoA]
- N-Calcium Channel Receptor Antagonists [MoA]
- Neprilysin Inhibitors [MoA]
- Neuraminidase Inhibitors [MoA]
- Neurokinin 1 Antagonists [MoA]
- NMDA Receptor Antagonists [MoA]
- Non-Nucleoside Reverse Transcriptase Inhibitors [MoA]
- Norepinephrine Uptake Inhibitors [MoA]
- Nucleic Acid Synthesis Inhibitors [MoA]
- Nucleoside Reverse Transcriptase Inhibitors [MoA]
- Opioid Agonists [MoA]
- Opioid Antagonists [MoA]
- Opioid mu-Receptor Agonists [MoA]
- Orexin Receptor Antagonists [MoA]
- Organic Anion Transporter 1 Inhibitors [MoA]
- Organic Anion Transporter 3 Inhibitors [MoA]
- Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
- Organic Anion Transporting Polypeptide 1B3 Inhibitors [MoA]
- Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]
- Organic Cation Transporter 1 Inhibitors [MoA]
- Organic Cation Transporter 2 Inhibitors [MoA]
- Osmotic Activity [MoA]
- Oxidation-Reduction Activity [MoA]
- P2Y12 Receptor Antagonists [MoA]
- Partial Cholinergic Nicotinic Agonists [MoA]
- Partial Opioid Agonists [MoA]
- PCSK9 Inhibitors [MoA]
- Peroxisome Proliferator-activated Receptor Activity [MoA]
- Peroxisome Proliferator-activated Receptor alpha Agonists [MoA]
- P-Glycoprotein Inducers [MoA]
- P-Glycoprotein Inhibitors [MoA]
- P-Glycoprotein Interactions [MoA]
- Phenylalanine Hydroxylase Activators [MoA]
- Phosphate Chelating Activity [MoA]
- Phosphodiesterase 3 Inhibitors [MoA]
- Phosphodiesterase 4 Inhibitors [MoA]
- Phosphodiesterase 5 Inhibitors [MoA]
- Photoabsorption [MoA]
- Poly(ADP-Ribose) Polymerase Inhibitors [MoA]
- Polymerase Acidic Endonuclease Inhibitors [MoA]
- Positron Emitting Activity [MoA]
- Potassium Channel Antagonists [MoA]
- Potassium Ion Binding Activity [MoA]
- Progestational Hormone Receptor Antagonists [MoA]
- Programmed Death Ligand-1 Antagonists [MoA]
- Programmed Death Ligand-1-directed Antibody Interactions [MoA]
- Programmed Death Receptor-1-directed Antibody Interactions [MoA]
- Prostacyclin Receptor Agonists [MoA]
- Prostaglandin Receptor Agonists [MoA]
- Protease-activated Receptor-1 Antagonists [MoA]
- Proteasome Inhibitors [MoA]
- Protein Kinase Inhibitors [MoA]
- Protein Synthesis Inhibitors [MoA]
- Proton Pump Inhibitors [MoA]
- Radiopharmaceutical Activity [MoA]
- RANK Ligand Blocking Activity [MoA]
- Receptor Tyrosine Kinase Inhibitors [MoA]
- Reduction Activity [MoA]
- Renin Inhibitors [MoA]
- Rho Kinase Inhibitors [MoA]
- RNA Replicase Inhibitors [MoA]
- RNA Synthetase Inhibitors [MoA]
- Sclerosing Activity [MoA]
- Selective Estrogen Receptor Modulators [MoA]
- Selective Progesterone Receptor Modulators [MoA]
- Serotonin 1b Receptor Agonists [MoA]
- Serotonin 1d Receptor Agonists [MoA]
- Serotonin 2c Receptor Agonists [MoA]
- Serotonin 3 Receptor Antagonists [MoA]
- Serotonin 4 Receptor Antagonists [MoA]
- Serotonin Uptake Inhibitors [MoA]
- Sigma-1 Receptor Agonists [MoA]
- SLAMF7-directed Antibody Interactions [MoA]
- Smoothened Receptor Antagonists [MoA]
- Sodium-Glucose Transporter 2 Inhibitors [MoA]
- Somatostatin Receptor Agonists [MoA]
- Sphingosine 1-Phosphate Receptor Modulators [MoA]
- Surfactant Activity [MoA]
- Thrombin Inhibitors [MoA]
- Thrombopoietin Receptor Agonists [MoA]
- Thymidine Phosphorylase Inhibitors [MoA]
- Thyroid Hormone Synthesis Inhibitors [MoA]
- Topoisomerase Inhibitors [MoA]
- Trypsin Inhibitors [MoA]
- Tryptophan Hydroxylase Inhibitors [MoA]
- Tumor Necrosis Factor Receptor Blocking Activity [MoA]
- Tyrosine Kinase Inhibitors [MoA]
- UDP Glucuronosyltransferases Inducers [MoA]
- UDP Glucuronosyltransferases Inhibitors [MoA]
- UGT1A1 Inhibitors [MoA]
- UGT1A3 Inhibitors [MoA]
- UGT1A4 Inhibitors [MoA]
- UGT1A6 Inhibitors [MoA]
- UGT1A9 Inhibitors [MoA]
- UGT2B15 Inhibitors [MoA]
- UGT2B7 Inhibitors [MoA]
- Ultrasound Contrast Activity [MoA]
- Uncompetitive NMDA Receptor Antagonists [MoA]
- Urate Transporter 1 Inhibitors [MoA]
- Urease Inhibitors [MoA]
- Vascular Endothelial Growth Factor-directed Antibody Interactions [MoA]
- Vascular Endothelial Growth Factor Inhibitors [MoA]
- Vasopressin Receptor Antagonists [MoA]
- Vasopressin V2 Receptor Antagonists [MoA]
- VEGFR2 Inhibitors [MoA]
- Venom Neutralization [MoA]
- Vesicular Monoamine Transporter 2 Inhibitors [MoA]
- Virus Neutralization [MoA]
- Vitamin K Inhibitors [MoA]
- Xanthine Oxidase Inhibitors [MoA]
- X-Ray Contrast Activity [MoA]